Compare EOD & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOD | CDXS |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | EOD | CDXS |
|---|---|---|
| Price | $6.49 | $2.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 121.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $5.14 | $0.96 |
| 52 Week High | $6.49 | $3.87 |
| Indicator | EOD | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 62.29 |
| Support Level | $5.56 | $2.37 |
| Resistance Level | N/A | $2.92 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 95.71 | 71.32 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.